By Dipo Olowookere
In its efforts to make it impossible to counterfeit its products, MeCure Industries Plc has implemented a cutting-edge technology known as Track and Trace Solution.
A statement issued by the healthcare firm disclosed that this new device, which can be used to monitor the movement of products from its manufacturing facility to the ultimate recipient, was designed to ensure “product safety for our customers.”
According to the disclosure sighted by Business Post, 18 brands within the MeCure portfolio have been enabled with this technology, with the company promising that all of its over 50 brands to be “traceable by the end of the first quarter of 2024.”
The organisation said this new initiative is poised to serve as a beacon for public health, guaranteeing that patients receive authentic and life-saving treatments, noting that the tracking of its products would facilitate the prompt identification of potential issues or discrepancies, thereby enabling timely corrective actions.
“Any suspicious deviation in the supply chain or an unauthorised alteration of product information can be flagged by the Track and Trace programme for the stakeholders to intervene expeditiously, curtailing the dissemination of counterfeit drugs and safeguarding unsuspecting consumers,” a part of the notice said.
The statement boasted that, “MeCure Track and Trace enabled brands are impossible to counterfeit,” as every stage of a drug’s trajectory is traceable and verifiable through this technology it developed with the collaboration of ACG Inspection, with the support of the National Agency for Food and Drug Administration and Control (NAFDAC), especially its Director-General, Mrs Mojisola Adeyeye, for her “visionary leadership in consistently staying at the forefront of innovative solutions such as Track and Trace.”
MeCure said counterfeit drugs pose a “profound risk to public health” in the form of incorrect ingredients, improper dosages, or deleterious substances, stressing that the ramifications of consuming them “span from therapeutic inefficacy to life-threatening complications.”
